NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: Cytokine gene expression profiling and in vivo bioluminescent imaging

Veterinary and Comparative Oncology

Volumn 6, Issue 1, 2008, Pages 39-54

  Nadella, M V P ^a   Kisseberth, W C ^a   Nadella, K S ^a   Thudi, N K ^a   Thamm, D H ^b   Mcniel, E A ^c   Yilmaz, A ^a   Boris Lawrie, K ^a   Rosol, T J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bioluminescent imaging canine lymphoma; Humoral hypercalcaemia of malignancy; PTHrP; Xenograft

Indexed keywords

ANIMALIA; CANIS FAMILIARIS; LENTIVIRUS; MUS;

CALCIUM; CYTOKINE; LUCIFERASE; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOSYNTHESIS; BLOOD; CANCER TRANSPLANTATION; DISEASE MODEL; DOG; DOG DISEASE; FEMALE; GENETICS; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; LUMINESCENCE; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LYMPHOMA; XENOGRAFT;

ANIMALS; CALCIUM; CYTOKINES; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; FEMALE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; LUCIFERASES; LUMINESCENT MEASUREMENTS; LYMPHOMA, T-CELL; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PARATHYROID HORMONE-RELATED PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 61549138693     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2007.00139.x     Document Type: Article

References (64)

1. O'Connor OA, Toner LE, Vrhovac R, Budak-Alpdogan T, Smith EA and Bergman P. Comparative animal models for the study of lymphohematopoietic tumors: Strengths and limitations of present approaches. Leukemia & Lymphoma 2005; 46: 973-992.
2. Sueiro FA, Alessi AC and Vassallo J. Canine lymphomas: A morphological and immunohistochemical study of 55 cases, with observations on p53 immunoexpression. Journal of Comparative Pathology 2004; 131: 207-213.
3. Teske E. Canine malignant lymphoma: A review and comparison with human non-Hodgkin's lymphoma. Veterinary Quarterly 1994; 16: 209-219.
4. MacEwen EG. Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment. Cancer Metastasis Reviews 1990; 9: 125-136.
5. Washizu T, Azakami D, Bonkobara M, Washizu M and Arai T. Changes in activities of enzymes related to energy metabolism in canine lymphoma cells. Journal of Veterinary Medical Science 2005; 67: 615-616.
6. Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R, Avery PR, Lindblad-Toh K, Ostrander EA, Cutter GC and Avery AC. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Research 2005; 65: 5654-5661.
7. Fournel-Fleury C, Magnol JP, Bricaire P, Marchal T, Chabanne L, Delverdier A, Bryon PA and Felman P. Cytohistological and immunological classification of canine malignant lymphomas: Comparison with human non-Hodgkin's lymphomas. Journal of Comparative Pathology 1997; 117: 35-59.
8. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-3918.
9. Fournel-Fleury C, Ponce F, Felman P, Blavier A, Bonnefont C, Chabanne L, Marchal T, Cadore JL, Goy-Thollot I, Ledieu D, Ghernati I and Magnol JP. Canine T-cell lymphomas: A morphological, immunological, and clinical study of 46 new cases. Veterinary Pathology 2002; 39: 92-109.
10. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA and Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Annals of Internal Medicine 1994; 121: 633-640.
11. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T and Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: Overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 2002; 99: 634-640.
12. Rosol TJ and Capen CC. Mechanisms of cancer-induced hypercalcemia. Laboratory Investigation 1992; 67: 680-702.
13. Mundy GR and Guise TA. Hypercalcemia of malignancy. American Journal of Medicine 1997; 103: 134-145.
14. Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997; 80(Suppl): 1557-1563.
15. Meuten DJ, Kociba GJ, Capen CC, Chew DJ, Segre GV, Levine L, Tashjian AH, Jr, Voelkel EF and Nagode LA. Hypercalcemia in dogs with lymphosarcoma. Biochemical, ultrastructural, and histomorphometric investigations. Laboratory Investigation 1983; 49: 553-562.
16. Yoneda T, Alsina MA, Chavez JB, Bonewald L, Nishimura R and Mundy GR. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. Journal of Clinical Investigation 1991; 87: 977-985.
17. Mundy GR. Pathophysiology of cancer-associated hypercalcemia. Seminars in Oncology 1990; 17(Suppl. 5): 10-15.
18. Johnson RA, Boyce BF, Mundy GR and Roodman GD. Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology 1989; 124: 1424-1427.
19. Seymour JF and Gagel RF. Calcitriol: The major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82: 1383-1394.
20. Wano Y, Hattori T, Matsuoka M, Takatsuki K, Chua AO, Gubler U and Greene WC. Interleukin 1 gene expression in adult T cell leukemia. Journal of Clinical Investigation 1987; 80: 911-916.
21. Niitsu Y, Urushizaki Y, Koshida Y, Terui K, Mahara K, Kohgo Y and Urushizaki I. Expression of TGF-beta gene in adult T cell leukemia. Blood 1988; 71: 263-266.
22. Firkin F, Seymour JF, Watson AM, Grill V and Martin TJ. Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. British Journal of Haematology 1996; 94: 486-492.
23. Rosol TJ and Capen CC. Pathogenesis of humoral hypercalcemia of malignancy. Domestic Animal Endocrinology 1988; 5: 1-21.
24. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ and Stewart AF. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. New England Journal of Medicine 1988; 319: 556-563.
25. Wysolmerski JJ and Broadus AE. Hypercalcemia of malignancy: The central role of parathyroid hormone-related protein. Annual Review of Medicine 1994; 45: 189-200.
26. Kukreja SC, Shevrin DH, Wimbiscus SA, Ebeling PR, Danks JA, Rodda CP, Wood WI and Martin TJ. Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. Journal of Clinical Investigation 1988; 82: 1798-1802.
27. Caulfield MP, McKee RL, Goldman ME, Thiede MA, Thompson DD, Fisher JE, Levy JJ, Seedor JG, Horiuchi N and Clemens TL. Parathyroid hormone-related protein (PTHrP): Studies with synthetic peptides indicate that parathyroid hormone and PTHrP interact with the same receptor. International Journal of Radiation Applications and Instrumentation B 1990; 17: 633-637.
28. Rosenblatt M, Caulfield MP, Fisher JE, Horiuchi N, McKee RL, Rodan SB, Thiede MA, Thompson DD, Seedor JG and Nutt RE. A tumor-secreted protein associated with human hypercalcemia of malignancy. Biology and molecular biology. Annals of the New York Academy Sciences 1988; 548: 137-145.
29. Rosol TJ, Nagode LA, Couto CG, Hammer AS, Chew DJ, Peterson JL, Ayl RD, Steinmeyer CL and Capen CC. Parathyroid hormone (PTH)-related protein, PTH, and 1,25-dihydroxyvitamin D in dogs with cancer-associated hypercalcemia. Endocrinology 1992; 131: 1157-1164.
30. Clines GA and Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocrine-Related Cancer 2005; 12: 549-583.
31. Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, Roodman GD and Guise TA. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Research 1997; 57: 3194-3199.
32. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJ and Mundy GR. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989; 125: 1142-1150.
33. Modiano JF, Breen M, Valli VE, Wojcieszyn JW and Cutter GR. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma. Leukemia 2007; 21: 184-187.
34. Starkey MP, Scase TJ, Mellersh CS and Murphy S. Dogs really are man's best friend - canine genomics has applications in veterinary and human medicine! Briefings in Functional Genomics & Proteomics 2005; 4: 112-128.
35. Vail DM and MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000; 18: 781-792.
36. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM and Anderson KC. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: Biologic and clinical implications. Cancer Research 2003; 63: 6689-6696.
37. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH and Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003; 101: 640-648.
38. Mellersh CS, Langston AA, Acland GM, Fleming MA, Ray K, Wiegand NA, Francisco LV, Gibbs M, Aguirre GD and Ostrander EA. A linkage map of the canine genome. Genomics 1997; 46: 326-336.
39. Ostrander EA, Mapa FA, Yee M and Rine J. One hundred and one new simple sequence repeat-based markers for the canine genome. Mammalian Genome 1995; 6: 192-195.
40. Peeters D, Peters IR, Clercx C and Day MJ. Real-time RT-PCR quantification of mRNA encoding cytokines, CC chemokines and CCR3 in bronchial biopsies from dogs with eosinophilic bronchopneumopathy. Veterinary Immunology and Immunopathology 2006; 110: 65-77.
41. Peeters D, Peters IR, Farnir F, Clercx C and Day MJ. Real-time RT-PCR quantification of mRNA encoding cytokines and chemokines in histologically normal canine nasal, bronchial and pulmonary tissue. Veterinary Immunology and Immunopathology 2005; 104: 195-204.
42. Aihara Y, Kasuya H, Onda H, Hori T, Takeda J and Faraci FM. Quantitative analysis of gene expressions related to inflammation in canine spastic artery after subarachnoid hemorrhage [editorial comment]. Stroke 2001; 32: 212-217.
43. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H and Rosol TJ. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clinical and Experimental Metastasis 2006;23: 19-31.
44. Richard V, Lairmore MD, Green PL, Feuer G, Erbe RS, Albrecht B, D'Souza C, Keller ET, Dai J and Rosol TJ. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. American Journal of Pathology 2001; 158: 2219-2228.
45. Staudt LM. Gene expression profiling of lymphoid malignancies. Annual Review of Medicine 2002; 53: 303-318.
46. An HX, Beckmann MW, Reifenberger G, Bender HG and Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. American Journal of Pathology 1999; 154: 113-118.
47. Hernandez L, Bea S, Pinyol M, Ott G, Katzenberger T, Rosenwald A, Bosch F, Lopez-Guillermo A, Delabie J, Colomer D, Montserrat E and Campo E. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Research 2005; 65: 2199-2206.
48. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC and Chaganti RSK. Chromosomal and gene amplification in diffuse large B-Cell lymphoma. Blood 1998; 92: 234-240.
49. Patra SK, Patra A and Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochemical Biophysical Research Communications 2001; 287: 705-713.
50. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I and Coombes RC. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clinical Cancer Research 2001; 7: 971-976.
51. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ and Kim DY. Expression profile of histone deacetylase 1 in gastric cancer tissues. Japanese Journal of Cancer Research 2001; 92: 1300-1304.
52. Aoudjit F, Potworowski EF and St Pierre Y. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. Journal of Immunology 1998; 160: 2967-2973.
53. Jin H and Varner J. Integrins: Roles in cancer development and as treatment targets. British Journal of Cancer 2004; 90: 561-565.
54. Drillenburg P and Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood 2000; 95: 1900-1910.
55. Schweighoffer T, Tanaka Y, Tidswell M, Erle DJ, Horgan KJ, Luce GE, Lazarovits AI, Buck D and Shaw S. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with hallmarks of gut-trophism. Journal of Immunology 1993; 151: 717-729.
56. Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW and Koeffler HP. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001; 98: 787-794.
57. Gerber B, Hauser B and Reusch CE. Serum levels of 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol in dogs with hypercalcaemia. Veterinary Research Communications 2004; 28: 669-680.
58. Kukreja SC, Rosol TJ, Wimbiscus SA, Shevrin DH, Grill V, Barengolts EI and Martin TJ. Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer. Endocrinology 1990; 127: 305-310.
59. Kubota A, Kano R, Mizuno T, Hisasue M, Moore PF, Watari T, Tsujimoto H and Hasegawa A. Parathyroid hormone-related protein (PTHrP) produced by dog lymphoma cells. Journal of Veterinary Medical Science 2002; 64: 835-837.
60. Azuma Y, Kaji K, Katogi R, Takeshita S and Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. Journal of Biological Chemistry 2000; 275: 4858-4864.
61. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ and Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/ RANKL-RANK interaction. Journal of Experimental Medicine 2000; 191: 275-286.
62. Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O and Ferracini R. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. Federation of American Societies for Experimental Biology Journal 2005; 19: 228-230.
63. Theill LE, Boyle WJ and Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annual Review of Immunology 2002; 20: 795-823.
64. Cox M and Haddad JG. Lymphoma, hypercalcemia, and the sunshine vitamin. Annals of Internal Medicine 1994; 121: 709-712.